Skip to main content

Leuprolide News

Enzalutamide + Leuprolide Top for Mets-Free Survival in Prostate Cancer

WEDNESDAY, Oct. 18, 2023 – For patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus leuprolide is best for metastasis-free survival, according to a study published...

FDA Approves Camcevi (leuprolide mesylate) for the Treatment of Advanced Prostate Cancer

TAIPEI, May 26, 2021 /PRNewswire/ – Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for...

FDA Approves Fensolvi (leuprolide acetate) for Injectable Suspension for Pediatric Patients with Central Precocious Puberty

BUFFALO GROVE, Ill., May 4, 2020 /PRNewswire/ – Tolmar Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application for Fensolvi...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Prostate Cancer, Endometriosis, Uterine Leiomyomata / Fibroids, Breast Cancer - Adjuvant, Female Infertility

Related drug support groups

Lupron, Lupron Depot

Leuprolide patient information at Drugs.com